• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Entasis Therapeutics Holdings Inc. (Amendment)

    2/14/22 11:43:54 AM ET
    $ETTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETTX alert in real time by email
    SC 13G/A 1 entasis_sc13ga.htm SC 13G/A

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    Entasis Therapeutics Holdings, Inc.

    (Name of Issuer – as specified in its charter)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    293614103

    (CUSIP Number)

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    þ        Rule 13d-1(b)

    ¨        Rule 13d-1(c)

    ¨        Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Eventide Asset Management, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    590,602

     

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    590,602

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    590,602

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.2%

     

    12

    TYPE OF REPORTING PERSON

    IA

           

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Finny Kuruvilla, M.D. Ph. D.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    590,602

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    590,602

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    590,602

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.2%

     

    12

    TYPE OF REPORTING PERSON

    IN;HC

           

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Robin C. John

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    590,602

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    590,602

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    590,602

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.2%

     

    12

    TYPE OF REPORTING PERSON

    IN;HC

           

     

     
     

    Item 1. (a) Name of Issuer:

    Entasis Therapeutics Holdings, Inc. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices:

    35 Gatehouse Drive, Waltham, Massachusetts 02451

    Item 2. (a) Name of Persons Filing:

    (i) Eventide Asset Management, LLC (“Eventide”)

    (ii) Finny Kuruvilla, M.D., Ph.D. (“Kuruvilla”)

    (iii) Robin C. John (“John”)

    (b). Address of Principal Business Office or, if none, Residence:

    Eventide, Kuruvilla and John:

    One International Place, Suite 4210

    Boston, Massachusetts 02110

    (c). Citizenship or Place of Organization:

    Eventide: Delaware

    Kuruvilla: United States

    John: United States

    (d). Title of Class of Securities:

    Common Stock, $0.001 par value

     

    (e). CUSIP Number:

    293614103

    Item 3. If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

    (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

    (e) [x] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E);

    (f) [ ] An employee benefit plan or endowment fund in accordance with section 240.13d- 1(b)(1)(ii)(F);

    (g) [x] A parent holding company or control person in accordance with section 240.13d- 1(b)(1)(ii)(G);

    (h) [ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance

    Act (12 U.S.C. 1813);

    (i) [ ] A church plan that is excluded from the definition of an investment company under

     
     

            section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J);

    (k) [ ] A group, in accordance with section 240.13d-1(b)(1) (ii)(K).

    If filing as a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

    Item 4. Ownership:

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

    (a). Amount beneficially owned:

    (i) Eventide:   590,602 
    (ii) Kuruvilla:   590,602 
    (iii) John:   590,602 

     

    (b). Percent of class:

    (i) Eventide:   1.2%
    (ii) Kuruvilla:   1.2%
    (iii) John:   1.2%

     

    (c). Number of shares as to which the person has:

    (i)        Sole power to vote or to direct the vote:

     (1) Eventide:    590,602 
     (2) Kuruvilla:    0 
     (3) John:    0 

     

    (ii)        Shared power to vote or to direct the vote:

     

     (1) Eventide:    0 
     (2) Kuruvilla:    590,602 
     (3) John:    590,602 

     

    (iii) Sole power to dispose or to direct the disposition of:

     (1) Eventide:    590,602 
     (2) Kuruvilla:    0 
     (3) John:    0 

     

    (iv) Shared power to dispose or to direct the disposition of:

     (1) Eventide:    0 
     (2) Kuruvilla:    590,602 
     (3) John:    590,602 
     
     

    Item 5. Ownership of Five Percent or Less of a Class:

    This statement is being filed to report the fact that as of the date hereof Eventide Asset Management, LLC has ceased to be the beneficial owner of more than five percent of the Issuer’s outstanding Common Stock.

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person:

    Not Applicable

    Item 7.Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

    Not Applicable

    Item 8. Identification and Classification of Members of the Group:

    Not Applicable

    Item 9. Notice of Dissolution of Group:

    Not Applicable

    Item 10.Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

     
     

    SIGNATURES

     

    The undersigned certify, after reasonable inquiry and to the best knowledge and belief of the undersigned, that the information set forth in this Statement is true, complete and correct. The undersigned agree to the filing of this single Statement on Schedule 13G.

     

    Eventide Asset Management, LLC

    Date: February 14, 2022                                    By: /s/ Peter J. Luiso

    Name: Peter J. Luiso

    Title: Chief Compliance Officer

    and General Counsel

    Finny Kuruvilla, M.D., Ph. D.

    Date: February 14, 2022                                     By: /s/ Finny Kuruvilla, M.D., Ph. D.

    Name: Finny Kuruvilla, M.D., Ph. D.

    Robin C. John

    Date: February 14, 2022                                     By: /s/ Robin C. John

    Name: Robin C. John

     
     

     

    EXHIBIT 1

    WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them;

    NOW, THEREFORE, the parties hereto agree as follows:

    Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them.

    Eventide Asset Management, LLC

    Date: February 14, 2022                                     By: /s/ Peter J. Luiso

    Name: Peter J. Luiso

    Title: Chief Compliance Officer

    and General Counsel

    Finny Kuruvilla, M.D., Ph. D.

    Date: February 14, 2022                                     By: /s/ Finny Kuruvilla, M.D., Ph. D.

    Name: Finny Kuruvilla, M.D., Ph. D.

    Robin C. John

    Date: February 14, 2022                                    By: /s/ Robin C. John

    Name: Robin C. John

    Get the next $ETTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ETTX

    DatePrice TargetRatingAnalyst
    3/8/2022$9.00 → $1.80Outperform → Neutral
    Wedbush
    3/4/2022$6.00 → $1.80Buy → Neutral
    HC Wainwright & Co.
    10/20/2021$5.00 → $7.00Outperform
    BMO Capital
    10/19/2021$5.00 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ETTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Entasis Therapeutics Holdings Inc. (Amendment)

      SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)

      7/11/22 5:27:19 PM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Entasis Therapeutics Holdings Inc. (Amendment)

      SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)

      5/23/22 8:55:33 PM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Entasis Therapeutics Holdings Inc. (Amendment)

      SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)

      3/15/22 9:00:21 AM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Innoviva, Inc. bought $42,395,047 worth of shares (19,270,476 units at $2.20)

      4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)

      7/13/22 9:27:34 PM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Wagner Kristie Ann returned 80,500 shares to the company, closing all direct ownership in the company

      4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)

      7/11/22 4:11:00 PM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Triola Anna Diaz returned 125,000 shares to the company, closing all direct ownership in the company

      4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)

      7/11/22 4:10:15 PM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial Officer

      – Significant commercial strategy and product launch experience –– ATTACK Phase 3 top-line data readout remains on-track for 2H 2021 – WALTHAM, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the appointment of Anna Diaz Triola as Chief Commercial Officer, effective July 19th 2021. Ms. Triola will be responsible for global commercial strategy, including U.S. sales and marketing operations. "With the ATTACK Phase 3 registration clinical trial nearing completion, we are now engaged in preparing for commercialization

      7/14/21 8:00:00 AM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Entasis Therapeutics Hldg downgraded by Wedbush with a new price target

      Wedbush downgraded Entasis Therapeutics Hldg from Outperform to Neutral and set a new price target of $1.80 from $9.00 previously

      3/8/22 7:04:37 AM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entasis Therapeutics Hldg downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Entasis Therapeutics Hldg from Buy to Neutral and set a new price target of $1.80 from $6.00 previously

      3/4/22 7:10:02 AM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital reiterated coverage on Entasis Therapeutics Hldg with a new price target

      BMO Capital reiterated coverage of Entasis Therapeutics Hldg with a rating of Outperform and set a new price target of $7.00 from $5.00 previously

      10/20/21 7:59:53 AM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ETTX
    SEC Filings

    See more
    • Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022

      WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (NASDAQ:INVA), today announced that six abstracts highlighting sulbactam-durlobactam (SUL-DUR) have been selected for presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C. Details of the presentations are as follows: Oral Presentations: Title: Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: sulbactam-durlobactam

      10/12/22 8:30:00 AM ET
      $ETTX
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.

      Innoviva, Inc. (NASDAQ:INVA) ("Innoviva") today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis") at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022. The depositary for the tender offer has advised that, as of the expiration of the tender offer, a total of 11,671,662 shares of Entasis' common stock were validly tendered and not withdrawn in the tender offer. Such shares of Entasis' common stock, upon excluding those tendered by Manoussos Perros (the "

      7/8/22 8:35:00 AM ET
      $ETTX
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference

      WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society for Microbiology (ASM) annual Microbe conference, taking place June 9-13, 2022, in Washington, DC. Entasis is presenting data on sulbactam-durlobactam (SUL-DUR), an investigational drug in development for the treatment of infections caused by Acinetobacter baumannii including carbapenem-resistant and multidrug-resistant (MDR) strains, and ETX0462 a novel, first-in-class, diazabicyclooctane with broad spectrum

      6/9/22 8:00:00 AM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Entasis Therapeutics Holdings Inc.

      15-12G - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)

      7/21/22 5:27:48 PM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Entasis Therapeutics Holdings Inc.

      EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)

      7/13/22 12:15:06 AM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Entasis Therapeutics Holdings Inc.

      EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)

      7/13/22 12:15:20 AM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETTX
    Financials

    Live finance-specific insights

    See more
    • Innoviva Reports First Quarter 2022 Financial Results

      Royalties increased by 5% to $93.5 million in the first quarter of 2022, compared to the same quarter in 2021. Issued $261.0 million convertible senior notes due 2028 and repurchased a portion of the convertible subordinated notes due 2023. Invested $45.0 million into Armata Pharmaceuticals Inc. (NYSE:ARMP) ("Armata"), an anti-infectives leader. Made a non-binding offer to acquire and provided $15.0 million convertible debt financing to Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis"), an anti-infectives leader. Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") today reported financial results for the first quarter ended March 31, 2022. Gross royalty revenue

      4/27/22 5:11:00 PM ET
      $ARMP
      $ETTX
      $INVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

      Sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints from landmark Phase 3 ATTACK trialRobust dataset builds compelling case for SUL-DUR which if approved, could become the first, uniquely differentiated and life-saving treatment option for patients with Acinetobacter infectionsPreparing for commercialization ahead of NDA submission in mid-2022, under the leadership of newly appointed Chief Commercial Officer Anna Diaz TriolaEntasis' pathogen-directed platform and latest candidate ETX0462 highlighted by seminal publication in the prestigious scientific journal Nature WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX),

      11/4/21 7:30:00 AM ET
      $ETTX
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021

      WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report third quarter 2021 financial results before the market opens on November 4, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow management's prepared remarks. Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five min

      10/28/21 8:00:00 AM ET
      $ETTX
      Biotechnology: Pharmaceutical Preparations
      Health Care